Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.25 and traded as low as $0.2180. Northwest Biotherapeutics shares last traded at $0.2201, with a volume of 1,362,734 shares changing hands.
Northwest Biotherapeutics Trading Down 0.9%
The company has a market cap of $351.89 million, a price-to-earnings ratio of -0.01 and a beta of -0.81. The stock has a 50-day simple moving average of $0.26 and a 200-day simple moving average of $0.25.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Recommended Stories
- Five stocks we like better than Northwest Biotherapeutics
- Silver Is the New Oil—And the World’s Running Dry
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- What happened in Cyprus could be coming here
- Elon Musk’s $1 Quadrillion AI IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
